A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01).
Scott AJ, Basu Mallick A, Dotan E, Cohen SJ, Gold PJ, Hochster HS, Subramaniam S, Barzi A, Watts GS, Blatchford PJ, Messersmith WA. A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01). Cancer Res Commun. 2022 10; 2(10):1188-1196.